Calliditas Therapeutics: China – score!

Research Note

2019-06-10

09:09

Calliditas today announced that they have entered into a license agreement with Everest Medicines to develop and commercialize Nefecon in Greater China and Singapore for IgA Nephropathy. We have not included any deal for Asia in our model and today’s news will have a positive effect on our valuation.

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.